a wholly-owned subsidiary of Celgene (“Purchaser”), and Juno Therapeutics, Inc. (“Juno”). to the Merger Agreement, Purchaser will commence a tender offer to purchase all of the issued and outstanding shares of Juno s common stock, …
Even some of the biggest and best have things go wrong every now and then. Celgene (NASDAQ: CELG) has been the best-performing biotech stock over the last five years among big biotechs with market caps over $50 billion. And now, …
SmarTrend identified a Downtrend for Celgene Corp (NASDAQ:CELG) on October 13th, 2017 at $137.01. In approximately 2 months, Celgene Corp has returned 22.39% as of today's recent price of $106.33. In the past 52 weeks, shares of …
As the broader market rallied on Tuesday on the back of hopeful rhetoric around tax reform, the healthcare sector happily participated. The biotechnology subgroup of stocks also flocked higher, leaving plenty of so-called “bullish reversals” …
Celgene Corporation's (NASDAQ:CELG) stock were down more than 5% in premarket trade following news of a drug development disappointment. In after-hours on Thursday, the pharmaceutical firm announced it would not take a …
Shares of the Celgene Corporation rose 5.9 percent yesterday after regulators approved the company's Revlimid capsule for a rare blood cancer, a treatment that will cost pharmacies $215 to $225 a pill. The Food and Drug Administration …
If you're looking for a smart stock to buy right now, look no further than Celgene (NASDAQ: CELG). The big biotech has hit a rough patch lately, with a major clinical setback, missing third-quarter revenue expectations, and lowering its full …
Biotech stocks and the related ETFs have been the star performers this year despite some temporary glitches and …
The offer of $87 per share for the 90 percent of Juno that Celgene does not own sent Juno's stock soaring 27 percent to $86.31 in premarket trading. Shares of Celgene fell 1 percent to $101.60. The two companies said the deal, agreed by …
Celgene is under increasing pressure to replace revenue from its top-selling cancer treatment before copycat medicines eat into Revlimid sales. Its stock lost more than a quarter of its value during a five-day stretch in October after a highly …